1.17BMarket Cap-8809P/E (TTM)
12.940High12.170Low60.75KVolume12.720Open12.500Pre Close758.27KTurnover0.26%Turnover RatioLossP/E (Static)93.42MShares30.40052wk High19.37P/B295.65MFloat Cap4.80052wk Low--Dividend TTM23.63MShs Float5798.166Historical High--Div YieldTTM6.16%Amplitude0.854Historical Low12.482Avg Price1Lot Size
Gyre Therapeutics Stock Forum
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics (Nasdaq: GYRE), a biotech firm specializing in anti-fibrotic treatments, has received approval from China's NMPA for its Investigational New Drug (IND) application for F230. This drug, a selective endothelin receptor antagonist, is aimed at treating pulmonary arterial hypertension (PAH), a severe and progressive diso...
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average (.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index (.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index (.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks (DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...
This thing is insane. I bet an offering is in the works.
No comment yet